| |
Clinical benefit (n=8)
|
No clinical benefit (n=29)
|
P-value
|
|---|
|
Age
|
54.5 (49.0-59.25)
|
56.0 (43.5-64.5)
|
.986*
|
|
Male
|
8 (100%)
|
22 (75.9%)
|
.308†
|
|
BRAF Mutated
|
2/5 (40%)
|
9/19 (47.4%)
|
1.00†
|
|
Baseline ALC
|
1.50 (0.975-1.775)
|
1.30 (0.95-1.80)
|
.842*
|
|
LDH
|
203.5 (164.0-415.75)
|
244.0 (187.0-542.5)
|
.251*
|
|
Ulceration
|
2/6 (33.3%)
|
6/20 (30.0%)
|
1.00†
|
|
Prior Treatments
|
0/8 (0%)
|
7/29 (24.1%)
|
0.318†
|
|
Metastatic Subsets
|
|
IVA
|
2 (25%)
|
4 (13.8%)
|
.591†
|
|
IVB
|
1 (12.5%)
|
6 (20.7%)
|
1.0†
|
|
IVC
|
5 (62.5%)
|
19 (65.5%)
|
1.0†
|
-
†Fisher’s Exact test (reported as frequency(percent)).
- * Mann–Whitney U (reported as median (interquartile range)).
- ALC: Absolute Lymphocyte Count.
- LDH: Lactate Dehydrogenase.
